However, broad spectrum of immune evasion mechanisms let cancer cells escape from immune surveillance stimulated by using IC inhibitors in clinics (e.g., expression of alternative IC molecules such as TIM-3 after anti-PD-1 therapy) [18, 19]. This evidence concerns the gene HAVCR2 and cancer.